Stay updated with breaking news from Beijing Hanmi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(RTTNews) - Korea's Hanmi Pharmaceutical said it has entered into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. (MRK)...
LAPSTriple Agonist, an innovative triple-acting new drug for NASH treatment, indication expansion Efpeglenatide met the primary endpoint for global Phase 3 Striving for developing rare diseases such as a once-a-month drug for short-bowel syndrome SEOUL, South Korea, Jan. 18, 2021 /PRNewswire/ -- Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields. ...